Indinavir: Difference between revisions
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
'''Indinavir''' (IDV; trade name '''Crixivan''', manufactured by [[Merck & Co.|Merck]]) is a [[protease inhibitor (pharmacology)|protease inhibitor]] used as a component of [[antiretroviral drug|highly active antiretroviral therapy]] (HAART) to treat [[HIV]] infection and [[AIDS]]. | '''Indinavir''' (IDV; trade name '''Crixivan''', manufactured by [[Merck & Co.|Merck]]) is a [[protease inhibitor (pharmacology)|protease inhibitor]] used as a component of [[antiretroviral drug|highly active antiretroviral therapy]] (HAART) to treat [[HIV]] infection and [[AIDS]]. | ||
==Category== | ==Category== | ||
Revision as of 04:54, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Indinavir (IDV; trade name Crixivan, manufactured by Merck) is a protease inhibitor used as a component of highly active antiretroviral therapy (HAART) to treat HIV infection and AIDS.
Category
US Brand Names
CRIXIVAN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Dosage and Administration | How Supplied
Mechanism of Action
HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Indinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles.[1]
References
- ↑ "CRIXIVAN (INDINAVIR SULFATE) CAPSULE [MERCK SHARP & DOHME CORP.]". Text " accessdate" ignored (help)